Electromagnetic Field as a Factor of Universal Pathogenetic Therapy of Pulmonary Tuberculosis
Tuberculosis, Lung Diseases, HIV Infection · 11.05.2026 · (2) · 18-24
DOI: 10.30978/tb2026-2-18 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberculosis, Lung Diseases, HIV Infection, online erschienen am 11.05.2026. Verfasst von A.G. Yareshko und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Despite the fact that modern chemotherapy regimens for tuberculosis have significantly increased the effectiveness of its treatment, pathogenetic therapy remains a reserve for improving treatment. Objective — to clinically substantiate the effectiveness of the electromagnetic field of the physiological range as an important energy factor in the pathogenetic treatment of patients with drug-sensitive and drug-resistant pulmonary tuberculosis. Materials and methods. A study of the effectiveness of treatment of 200 patients with destructive pulmonary tuberculosis with bacterial excretion was conducted. According to the nature of treatment, patients were divided into 2 groups. The 1st group consisted of 88 patients in whom protocol antibacterial therapy was supplemented with information-wave therapy (IWT) as a pathogenetic treatment using the IWT device «Porih», which generates ultra-low intensity electromagnetic waves with a frequency of 0.1—100 GHz and an average spectral power density of 10–17—10–18 W ⋅ Hz/cm2. Exposure was performed remotely over reflexogenic zones identified on the skin surface. Patients received ≥ 20 IWT procedures. The 2nd group consisted of 112 patients who completed a course of antibacterial therapy according to the protocol. The groups did not differ by gender, age, clinical forms of pulmonary tuberculosis or the spectrum of pathogen resistance. Results and discussion. After the course of treatment, in the 1st group of patients with newly diagnosed pulmonary tuberculosis, cessation of bacterial excretion was observed in 62 (96.88 %), infiltration resorption in 58 (90.63 %) and closure of cavities in 56 (87.5 %); in the 2nd group — in 60 (68.97 %), 66 (75.86 %) and 54 (62.07 %, p < 0.05), respectively.After the completion of the treatment in patients with relapsed tuberculosis, objective indicators of treatment effectiveness differed significantly depending on the treatment regimen. In the 1st and 2nd groups, cessation of bacterial excretion was observed in 21 (87.5 %) and 12 (48.0 %, p < 0.01) cases; infiltration resorption in 17 (70.83 %) and 15 (60.0 %), and closure of decay cavities — 17 (70.83 %) and 10 (40.0 %, p < 0.01). Conclusions. The use of information-wave therapy in combination with treatment protocols for drug-sensitive and drug-resistant pulmonary tuberculosis significantly improves the effectiveness of antibacterial therapy, reduces treatment duration and increases the reliability of achieving cure, as well as significantly reduces treatment costs. The use of this method makes it possible to achieve the level of treatment effectiveness for tuberculosis recommended by WHO by 2035. Information-wave therapy has a pronounced detoxification effect, improves tolerance to chemotherapy and, as an energy-based method, has no contraindications.
Zitieren
APA
Yareshko, A., Kulish, M., Koptev, M., & Vorodyukhina, A. (2026). Electromagnetic Field as a Factor of Universal Pathogenetic Therapy of Pulmonary Tuberculosis. Tuberculosis, Lung Diseases, HIV Infection, 18-24. https://doi.org/10.30978/tb2026-2-18
Vancouver
Yareshko A, Kulish M, Koptev M, Vorodyukhina A. Electromagnetic Field as a Factor of Universal Pathogenetic Therapy of Pulmonary Tuberculosis. Tuberculosis, Lung Diseases, HIV Infection. 2026:18-24. doi:10.30978/tb2026-2-18
BibTeX
@article{Yareshko2026,
author = {Yareshko, A.G. and Kulish, M.V. and Koptev, M.M. and Vorodyukhina, A.K.},
title = {Electromagnetic Field as a Factor of Universal Pathogenetic Therapy of Pulmonary Tuberculosis},
journal = {Tuberculosis, Lung Diseases, HIV Infection},
year = {2026},
number = {2},
pages = {18--24},
doi = {10.30978/tb2026-2-18}
}
EUVIMED